OXBRYTA's market potential is driven by its novel mechanism targeting HbS polymerization in sickle cell disease, leading to strong hemoglobin improvements. Its convenient oral, once-daily dosing ...
EMPAVELI's key market opportunities include its strong differentiation through C3 inhibition, capturing PNH patients inadequately controlled by C5 inhibitors. Expansion into rare kidney diseases, ...
Detailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished Plenary Abstracts SessionCompany to ...
Objectives: Bidirectional endoscopy is recommended for new-onset iron deficiency anemia (IDA), given the risk of gastrointestinal (GI) cancer. The rate of endoscopic ass ...
FAQs on Preventive Care and Bodily Autonomy. The recent Supreme Court decision temporarily preserved nationwide access ...
Chemotherapy-induced anemia develops when chemotherapy drugs damage bone marrow cells that create red blood cells, reducing oxygen circulation throughout your body. About 70% of people receiving ...
Woman's World on MSN
4 blood tests every woman over 45 needs—are you asking for the wrong ones?
Women over 45 may not need hormone blood tests as often as they think, according to Pelin Batur, MD, of the Cleveland Clinic Women’s Comprehensive Health and Research Center. She says estradiol and ...
NDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated approval pathwayConfirmatory trial designed to ...
More people under 50 are being diagnosed with colorectal cancer.
The University of Arkansas for Medical Sciences Institute for Community Health Innovation has announced a new collaboration with the Berryville Community Center aim to eliminate barriers to fresh, ...
Doctors at Missouri and Kansas birthing hospitals have noticed an uptick in families turning down an inexpensive vitamin K ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results